AN2 Therapeutics COO sells 2,819 shares at $1.14 for RSU taxes

AN2 Therapeutics (ANTX) insider activity: Chief Operating Officer and Chief Legal Officer Joshua M. Eizen reported selling 2,819 shares of common stock at $1.14 on November 4, 2025, to satisfy tax withholding from RSU vesting.

Rhea-AI Filing Summary

AN2 Therapeutics (ANTX) insider activity: Chief Operating Officer and Chief Legal Officer Joshua M. Eizen reported selling 2,819 shares of common stock at $1.14 on November 4, 2025, to satisfy tax withholding from RSU vesting. Following the transaction, he beneficially owns 177,353 shares.

The holdings figure includes RSU grants: 31,500 RSUs vesting annually in quarters from November 4, 2024; 22,500 RSUs vesting annually in thirds from January 1, 2025; and 45,000 RSUs with two-thirds vesting on January 1, 2026 and one-third on July 1, 2026, subject to continuous service. The total also reflects the purchase of 5,000 shares under the 2022 ESPP on September 30, 2025.

Insider Trade Summary

Net Seller: 2,819 shares

Net Sell 1 txn

Insider Eizen Joshua M

Role See Remarks

Sold 2,819 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,819	$1.14	$3K

Holdings After Transaction: Common Stock — 177,353 shares (Direct)

Footnotes (3)

1. F1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on November 4, 2025.
2. F2. Includes, in accordance with the original terms, (a) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 (b) 22,500 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025 and (c) 45,000 RSUs which vest as follows: 2/3rd of the RSUs vest on January 1, 2026 and 1/3rd of the RSUs vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date.
3. F3. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ANTX insider Joshua M. Eizen report on Form 4?

He reported selling 2,819 shares of common stock at $1.14 on November 4, 2025 to cover RSU tax withholding.

How many ANTX shares does the insider hold after the transaction?

He beneficially owns 177,353 shares following the reported sale.

Why were the ANTX shares sold on November 4, 2025?

The sale was to satisfy tax withholding obligations arising from the vesting of RSUs on that date.

What RSU schedules are included in the insider’s holdings for ANTX?

RSUs include 31,500 vesting 1/4 annually from Nov 4, 2024; 22,500 vesting 1/3 annually from Jan 1, 2025; and 45,000 vesting 2/3 on Jan 1, 2026 and 1/3 on Jul 1, 2026.

Did the filing mention any recent ANTX share purchases by the insider?

Yes. It reflects a 5,000-share purchase under the 2022 ESPP on September 30, 2025.

What is the insider’s role at AN2 Therapeutics (ANTX)?

He is the company’s Chief Operating Officer and Chief Legal Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 06:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eizen Joshua M

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/04/2025		S		2,819(1)	D	$1.14	177,353(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on November 4, 2025.

2. Includes, in accordance with the original terms, (a) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 (b) 22,500 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025 and (c) 45,000 RSUs which vest as follows: 2/3rd of the RSUs vest on January 1, 2026 and 1/3rd of the RSUs vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date.

3. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2025.

Remarks:

Chief Operating Officer and Chief Legal Officer

	/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.